← PUMA BIOTECHNOLOGY, INC. (PBYI) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
PUMA BIOTECHNOLOGY, INC. (PBYI)
Pharmaceutical Preparations · market cap $501M · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
4
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Puma Biotechnology (PBYI) is a Los Angeles-based commercial-stage biopharmaceutical company with 265 employees and a ~$414M market cap. Its primary revenue engine is its HER2-targeted franchise, with lapatinib in Phase 3 for HER2+ metastatic breast cancer and neratinib also in Phase 3 for advanced breast cancer. The company has been consistently profitable on a net income basis since 2022, generating ~$228–236M in annual revenue with net income of $22–31M in the most recent three fiscal years.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Temsirolimus | Phase 2 | Breast Cancer |
| HKI-272 | Phase 2 | Carcinoma, Non-Small-Cell Lung |
| Alisertib | Phase 2 | Hormone Receptor Positive HER-2 Negative Breast Cancer |
| Neratinib | Phase 3 | Advanced Breast Cancer |
Price & technical context
3-month
+18.6%
6-month
+41.3%
12-month
+85.0%
52-wk range
$4.73–$9.93
vs 50-day MA
+7.9%
vs 200-day MA
+30.5%
Realized vol
60.3%
Max drawdown
-26.7%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for PBYI (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.